Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H10O3 |
| Molecular Weight | 130.1418 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)C(=O)C(O)=O
InChI
InChIKey=JVQYSWDUAOAHFM-BYPYZUCNSA-N
InChI=1S/C6H10O3/c1-3-4(2)5(7)6(8)9/h4H,3H2,1-2H3,(H,8,9)/t4-/m0/s1
| Molecular Formula | C6H10O3 |
| Molecular Weight | 130.1418 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:53:47 GMT 2025
by
admin
on
Mon Mar 31 17:53:47 GMT 2025
|
| Record UNII |
XQL9PAO004
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XQL9PAO004
Created by
admin on Mon Mar 31 17:53:47 GMT 2025 , Edited by admin on Mon Mar 31 17:53:47 GMT 2025
|
PRIMARY | |||
|
300000017394
Created by
admin on Mon Mar 31 17:53:47 GMT 2025 , Edited by admin on Mon Mar 31 17:53:47 GMT 2025
|
PRIMARY | |||
|
24809-08-3
Created by
admin on Mon Mar 31 17:53:47 GMT 2025 , Edited by admin on Mon Mar 31 17:53:47 GMT 2025
|
PRIMARY | |||
|
439286
Created by
admin on Mon Mar 31 17:53:47 GMT 2025 , Edited by admin on Mon Mar 31 17:53:47 GMT 2025
|
PRIMARY | |||
|
DTXSID20179505
Created by
admin on Mon Mar 31 17:53:47 GMT 2025 , Edited by admin on Mon Mar 31 17:53:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Useful in the treatment
of renal and hepatic disorders characterized by protein intolerance leading
to deficiencies of various essential and semi-essential amino acids in the body
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Used to treat severe renal failure (Chronic Uremia).
|
